1,026 Experimental treatments in acute stroke

Preclinical evaluation of neuroprotectants fostered high expectations of clinical efficacy. When not matched, the question arises whether experiments are poor indicators of clinical outcome or whether the best drugs were not taken forward to clinical trial. Therefore, we endeavored to contrast experimental efficacy and scope of testing of drugs used clinically and those tested only experimentally.

[1]  J. Stephenson.  World health report. , 2004, Lancet.

[2]  J. Krieglstein,et al.  Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents. , 1992, European journal of pharmacology.

[3]  A. Buchan,et al.  A Selective N-Type Ca2+-Channel Blocker Prevents CA1 Injury 24 h following Severe Forebrain Ischemia and Reduces Infarction following Focal Ischemia , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  D. Sackett,et al.  Cochrane Collaboration , 1994, BMJ.

[5]  G. D. del Zoppo.  Why do all drugs work in animals but none in stroke patients? 1. Drugs promoting cerebral blood flow. , 1995, Journal of internal medicine.

[6]  G. Zoppo.  Why do all drugs work in animals but none in stroke patients ? 1 Drugs promoting cerebral blood flow , 1995 .

[7]  D C Rogers,et al.  To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents? , 1998, Trends in pharmacological sciences.

[8]  N. Nagai,et al.  Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models. , 1999, Circulation.

[9]  W D Heiss,et al.  Which targets are relevant for therapy of acute ischemic stroke? , 1999, Stroke.

[10]  P. Lipton,et al.  Ischemic cell death in brain neurons. , 1999, Physiological reviews.

[11]  R. Ackerman,et al.  Effects of Tissue Type Plasminogen Activator in Embolic versus Mechanical Models of Focal Cerebral Ischemia in Rats , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  Z. Pei,et al.  [Effects of defibrinogenase on photochemically induced middle cerebral artery occlusion in stroke-prone renovascular hypertensive rats]. , 1999, Zhonghua yi xue za zhi.

[13]  Stroke Therapy Academic Industry Roundtable.  Recommendations for standards regarding preclinical neuroprotective and restorative drug development. , 1999, Stroke.

[14]  F. Sharp,et al.  Multiple Molecular Penumbras after Focal Cerebral Ischemia , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  Peter E. Hilsenrath,et al.  The World Health Report 2000 , 2002 .

[16]  J. Grotta.  Neuroprotection is unlikely to be effective in humans using current trial designs. , 2002, Stroke.

[17]  David J Gladstone,et al.  Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions , 2002, Stroke.

[18]  T. Odergren,et al.  Animal models of stroke: do they have value for discovering neuroprotective agents? , 2003, Trends in pharmacological sciences.

[19]  David W Howells,et al.  Pooling of Animal Experimental Data Reveals Influence of Study Design and Publication Bias , 2004, Stroke.

[20]  P. Sandercock,et al.  Where is the evidence that animal research benefits humans? , 2004, BMJ : British Medical Journal.

[21]  G. Donnan,et al.  Systematic review and meta‐analysis of the efficacy of melatonin in experimental stroke , 2005, Journal of pineal research.

[22]  G. Donnan,et al.  Systematic Review and Metaanalysis of the Efficacy of FK506 in Experimental Stroke , 2005, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[23]  Cor J. Kalkman,et al.  Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia , 2005, Journal of Neurology.